Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
106. |
ECCT/23/12/03 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Benson Ochieng Singa Site(s) in Kenya 1. Migori County Referral Hospital (Migori county) |
View |
107. |
ECCT/15/06/03 | DolutegrAvir With NRTIs as second-line treatment (DAWNING) A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy |
Principal Investigator(s) 1. Dr. Evans Inyangala Amukoye 2. Dr. Maricianah Atieno Onono Site(s) in Kenya 1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county) 2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county) |
View |
108. |
ECCT/21/07/05 | CARES A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa |
Principal Investigator(s) 1. Dr Reena Shah Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. KEMRI Walter Reed Project (Kericho county) 3. Moi University Clinical Research Centre (Uasin Gishu county) |
View |
109. |
ECCT/23/02/06 | BOHEMIA Safety and Efficacy A Phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in Kwale, Kenya. |
Principal Investigator(s) 1. Marta Ferreira Maia 2. Joseph Mwangangi Site(s) in Kenya Kwale county, subcounties Lungalunga and Msambweni |
View |
110. |
ECCT/20/10/04 | yellow fever vaccine CVIA 079 A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079. |
Principal Investigator(s) 1. Dr. Deborah Langat Site(s) in Kenya KEMRI/KERICHO CLINIC RESEARCH CENTRE |
View |